Suven gets US FDA nod for Nalgonda unit; scrip surges 10%
Press Trust of India / Mumbai May 06, 2009, 13:18 IST
Drug maker Suven Life today said it has received clearance from the US drug regulator for one of its active pharmaceutical ingredient facility located at Nalgonda in Andhra Pradesh.
"Based on the inspection and review, US Food and Drug Administration (US FDA) has classified Suven facility at Suryapet (Nalgonda) as acceptable for manufacture and supply of intermediates for active pharmaceutical ingredient (API's)," the Hyderabad-based firm informed stock exchanges.
"The company has undergone US FDA inspection at their intermediate/active pharmaceutical ingredient facility in Suryapet," Suven Life added.
According to the company, this is its second facility to have FDA's acceptance. In 2007, a unit of the company at Pashamylaram in Andhra Pradesh had received the approval from the US drug regulator for the supply of API's and intermediates.
Suven Life surged 10 per cent to hit upper circuit at Rs 15.85 on the Bombay Stock Exchange.
Content Guide
